# Research Query: Analyst earnings model assumptions on China recovery implications for Q2 guidance and revenue
**Generated:** Wednesday, August 27, 2025 at 12:20:12 PM
**Model:** gemini-2.5-flash

## Search Queries Used
- NVIDIA China revenue Q2 FY2026 guidance non-consensus
- NVIDIA China demand Q2 FY2026 supply chain reports
- NVIDIA China H20 L20 L2 sales Q2 FY2026
- NVIDIA analyst models China recovery Q2 FY2026
- NVIDIA China market share Q2 FY2026
- NVIDIA China AI chip sales Q2 FY2026 non-consensus
- NVIDIA Q2 FY2026 China export controls impact
- NVIDIA China data center revenue Q2 FY2026

## Sources Referenced
- [seekingalpha.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXTvlqiwT6pSHRtwSpkryBblWIJ0dVfbbX03MLSpp5W6K3dOb1qszjwtt_GJCYP8MUwPghh_6RLfPgKRxR9aD7QBJw3A1y4eqC2ZCRvBFJz7aJPRRSh3nezKQLsytg69KQ9OcoZurfQ2KqrXbpSqUuf0IeYidP5KVtkng6n3ZpzXLXEhbENnj1K38zDISYrq-fAEZr8m_x)
- [dig.watch](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHwRFpqUgSM5ExHDcIIk5FcemgOPPJdiuCmS65EgAQJk_STvxLHUl4f2wzUhbF5xvANZmoNURZT7Cf21SIzJj-wSkuwBmWAU2RB37b-kWWw9S33FQnCgAN3rWjnrkAdB1X_on0ZBW60PiUAcLdmsJV9hd6lGBuaO6TQlsGcTdIK4Fc_mW27s9R7bOh1dnT465U0PDHdZgNz)
- [ainvest.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHlyubX5-hxzbW-edRf5eGm-ZZhSrYUlDxNPIEZgv6zpZqsHDSgsVvYAvcd9VEs_ByE5_5vGQUVvGWdCgA-Xxomr2kCLaMlQNiBE7p780v-qqwVLV62Y-Z4LS4-yhjoJmC_lkbqtb8Dmk6OxMdhWFQ7hCH2yN2KDLdoz1oNCZk=)
- [ainvest.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH4_cIH3krc_FjqemUCLhT23V0d2EuqBnzaGVfxT9GbM5LSjrzsDFOafAw5CBcCCLEY21Bvkk8-JAYVxwzTGM6v5JBCJiNgLlLTYmuqvQCXDQgLG0acW_pvoUHQGRbtVLVoUI6fTAdhTs_HWKrxRmkqMFJ-PwEH0VNmtVHomJgOfsgb3lIWS82hQqVC8MQy3bT3TxZNgApLZUN9K3qxJR3KgUcrp0g56FCG)
- [ainvest.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF4Nq2aqiG0f7fyatR18Bj5TRVuAXVZ8CPlo5RjuA1mGA-geK6Mtsl5KysY_WmteKhJyrh0_JpibxSpn8i60qAL6hPleb-Sw8kNCsfppttfjcDJR0t9gtdASRpRfjLjqNs2TYn8Wwa5Muq3KxwbwOUD6bJiD1temg0d_NGUSJSkqgYX4m0vtf1Jez3mOcE5QyNKivkF7F4NfYykznGuHc0kcdWjy5AsfpyIoEIM0LXuyl8udw==)
- [seekingalpha.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE0QlKvpPzg8FLXE04kn5mTcl9aJN08Z1UW9KkuvrHHy_yvVhG2WZyrJ12zb1hF9oxovMAOMgUCqtFFDVQ8-oXY_Uci7mzotmfbWbducTjIGrzPq5Ao7vJ58CzOD0fE9msgly6K1mW9xhVSr-W_rME7bgtbfxN-EJUtJDRYpO5V00L96Rldi3F3bt008X8sUdXK71hTta13NSkaCakAvQgaCP8yimMzmLyGgtBHcIgIbjg=)
- [financialcontent.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGlOitNt3Gmq4tIumivz4B5Bj4VJRfshrDa455hzzESHFnI26CDFDMmT0ZbzlXO6B1KgIlIe6WnOQENArI7oYL1duMIvuKgQyo-btB7qmeYzG3Cwh-d3VGH6yphvJgnvH48OKp8dORUen-94KGgaROjE0ZdRlEnZSeGdbd6En9-bMR7f0p_H65fj86bZxmLDYLTRyDE2B2Zus_KvQEC_oGDurG6CUJBzVikvrakKMR8E0G968fOPCvFPRpSa1xKbRiXOjldMpCkoFBjeTWksYYZLXEKEufrZuLDUvu8FcJ8hMsD)

---

## Analysis

Here are the material, non-consensus findings regarding NVIDIA's (NVDA) upcoming Q2 FY2026 earnings report and forward-looking guidance, with a specific focus on China recovery implications:

**Human-Readable Analysis:**

NVIDIA is set to report its Q2 FY2026 earnings after market close today, August 27, 2025, with consensus revenue forecasts around $45.8-$46.5 billion, slightly above the company's own guidance of $45.0 billion (plus or minus 2%). This guidance had already factored in an $8 billion reduction due to prior H20 export restrictions to China. A significant development has been the reported agreement allowing NVIDIA to resume H20 chip sales to China, albeit with a 15% revenue-sharing condition with the U.S. government. While many analysts view this as a tailwind, several non-consensus points suggest a more complex picture for China's recovery.

A critical non-consensus report indicates that China itself might be rejecting NVIDIA's compliant H20 chips, shifting the geopolitical risk from U.S. export controls to actual demand within China. This directly contradicts the widely held expectation of a revenue boost from resumed H20 sales. Furthermore, some analysts, like KeyBanc Capital Markets, are more cautious, suggesting NVIDIA's Q3 guidance might exclude direct revenue from China due to ongoing uncertainties and pending license approvals, potentially leaving an additional $2-3 billion in China sales out of current outlooks. This implies that the "China recovery" might not be as straightforward or immediate as some anticipate.

Adding to the complexity, Chinese authorities are actively promoting domestic alternatives such as Huawei's Ascend chips, posing a structural headwind that could limit NVIDIA's long-term market share in the region, even with export approvals. On the other hand, some analysts, like BofA's Vivek Arya, hold a more bullish non-consensus view, forecasting Q2 revenue of $47 billion and a higher FY2026 sales outlook of $210-$215 billion, explicitly including a potential $5-$10 billion upside from resumed H20 sales in the second half of the fiscal year. This suggests a belief in a more robust and impactful China recovery, albeit with the revenue recognition potentially pushed to later quarters. Finally, broader supply chain checks from Wedbush indicate an exceptionally strong overall demand-to-supply ratio of 10:1 for NVIDIA's chips, which could potentially offset any lingering China-specific headwinds if other regions continue to perform strongly.

The key contradiction lies in whether China is actively accepting or rejecting the H20 chips, and the timing and magnitude of revenue recognition from the region. Investors should pay close attention to management's commentary on China demand, the actual impact of the revenue-sharing agreement on gross margins, and any updates on domestic competition.

---

**Structured Findings:**

**1. China Reportedly Rejecting H20 Chips**
*   **Snippet:** "However, a new report suggests China itself is rejecting Nvidia's compliant H20 chips, shifting the primary geopolitical risk from Washington, D.C., to Beijing."
*   **Date:** August 13, 2025
*   **Source:** Seeking Alpha, [https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXTvlqiwT6pSHRtwSpkryBblWIJ0dVfbbX03MLSpp5W6K3dOb1qszjwtt_GJCYP8MUwPghh_6RLfPgKRxR9aD7QBJw3A1y4eqC2ZCRvBFJz7aJPRRSh3nezKQLsytg69KQ9OcoZurfQ2KqrXbpSqUuf0IeYidP5KVtkng6n3ZpzXLXEhbENnj1K38zDISYrq-fAEZr8m_x]
*   **Impact:** High. This is a direct contradiction to the general positive sentiment around the resumption of H20 sales to China. If true, it implies a demand-side problem within China, not just a supply-side restriction from the US, which could significantly dampen expected China recovery revenue.
*   **Consensus Check:** Overlooked/Non-consensus. Most reports focus on the *ability* to sell H20 chips due to the US-China deal; this snippet highlights a potential *unwillingness* of China to buy them.

**2. KeyBanc's Cautious Q3 Guidance Outlook for China**
*   **Snippet:** "KeyBanc Capital Markets, in a recent note, predicted that Nvidia's Q3 guidance could be lower than the consensus due to uncertainties in China, reported Investing.com. The brokerage noted that Nvidia's outlook might “exclude direct revenue from China given pending license approvals and uncertainty on timing.” If sales from China were included, it could potentially boost revenues by an additional $2-3 billion."
*   **Date:** August 24, 2025
*   **Source:** AInvest (citing Investing.com), [https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHlyubX5-hxzbW-edRf5eGm-ZZhSrYUlDxNPIEZgv6zpZqsHDSgsVvYAvcd9VEs_ByE5_5vGQUVvGWdCgA-Xxomr2kCLaMlQNiBE7p780v-qqwVLV62Y-Z4LS4-yhjoJmC_lkbqtb8Dmk6OxMdhWFQ7hCH2yN2KDLdoz1oNCZk=]
*   **Impact:** Medium-High. While focused on Q3 guidance, it suggests that even if H20 sales are technically allowed, the actual revenue recognition from China might be delayed or excluded from NVIDIA's near-term outlook due to ongoing uncertainties, potentially leading to a "miss" on China-related upside expectations for Q2 or a conservative Q3 guide.
*   **Consensus Check:** Non-consensus. Most analysts are factoring in some level of China recovery, but KeyBanc's view suggests a more conservative approach by NVIDIA itself in its guidance.

**3. Chinese Promotion of Domestic Alternatives (Huawei Ascend)**
*   **Snippet:** "The H20 re-ramp in Q2 2026 is expected to contribute $8 billion in revenue, but Chinese authorities are actively promoting domestic alternatives like Huawei's Ascend."
*   **Date:** August 25, 2025
*   **Source:** AInvest, [https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH4_cIH3krc_FjqemUCLhT23V0d2EuqBnzaGVfxT9GbM5LSjrzsDFOafAw5CBcCCLEY21Bvkk8-JAYVxwzTGM6v5JBCJiNgLlLTYmuqvQCXDQgLG0acW_pvoUHQGRbtVLVoUI6fTAdhTs_HWKrxRmkqMFJ-PwEH0VNmtVHomJgOfsgb3lIWS82hQqVCyO_o_IeYidP5KVtkng6n3ZpzXLXEhbENnj1K38zDISYrq-fAEZr8m_x]
*   **Impact:** Medium. This highlights a structural, long-term headwind that could cap NVIDIA's China recovery even if export restrictions ease. It suggests that even if H20 chips are allowed and desired, China's strategic push for self-sufficiency could limit NVIDIA's market share over time.
*   **Consensus Check:** Widely known as a long-term risk, but the *active promotion* specifically impacting Q2/Q3 expectations for H20 re-ramp might be overlooked in short-term models.

**4. BofA's Bullish Q2/Q3 & FY2026 Outlook Including China Upside**
*   **Snippet:** "BofA Securities analyst Vivek Arya maintains a Buy rating on NVIDIA with a $220 price target, forecasting Q2 revenue of $47 bln, beating the $45.8 bln consensus, driven by strong sales momentum and long-term earnings potential. The analyst expects Q3 revenue of $54 bln and raised the fiscal 2026 sales forecast to $210-$215 bln, with projected pro forma EPS of $4.70-$4.80, compared to the consensus estimate of $4.38. Arya attributes the expected beat-and-raise to continued strength in Blackwell and Blackwell Ultra, rising AI-related capex from hyperscalers, and the potential $5-$10 bln upside from resumed H20 sales in the second half."
*   **Date:** August 4, 2025
*   **Source:** AInvest (citing Investing.com), [https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF4Nq2aqiG0f7fyatR18Bj5TRVuAXVZ8CPlo5RjuA1mGA-geK6Mtsl5KysY_WmteKhJyrh0_JpibxSpn8i60rAL6hPleb-Sw8kNCsfppttfjcDJR0t9gtdASRpRfjLjqNs2TYn8Wwa5Muq3KxwbwOUD6bJiD1temg0d_NGUSJSkqgYX4m0vtf1Jez3mOcE5QyNKivkF7F4NfYykznGuHc0kcdWjy5AsfpyIoEIM0LXuyl8udw==]
*   **Impact:** Medium. This represents a more bullish non-consensus view on both Q2 performance and the overall FY2026 outlook, explicitly incorporating a significant China recovery in the second half. If NVIDIA beats Q2 and provides strong Q3/FY2026 guidance, it could align with this higher-end analyst expectation.
*   **Consensus Check:** Non-consensus (higher end). While many analysts are above NVIDIA's guidance, Arya's specific numbers and the explicit $5-$10 billion China upside in H2 are more aggressive than the general sentiment.

**5. Wedbush's 10:1 Demand-to-Supply Ratio**
*   **Snippet:** "Wedbush said recent checks showed demand to supply is a 10 to 1 ratio ahead of the company's earnings report, set for Aug. 27. ... “When Nvidia reports earnings this week on Wednesday after the bell the tech world and Wall Street will be listening closely to every word from Jensen as we continue to believe from our Asia field checks that demand to supply is 10:1 for Nvidia's golden chips,” Wedbush analysts wrote in a note to clients."
*   **Date:** August 25, 2025
*   **Source:** Seeking Alpha, [https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE0QlKvpPzg8FLXE04kn5mTcl9aJN08Z1UW9KkuvrHHy_yvVhG2WZyrJ12zb1hF9oxovMAOMgUCqtFFDVQ8-oXY_Uci7mzotmfbWbducTjIGrzPq5Ao7vJ58CzOD0fE9msgly6K1mW9xhVSr-W_rME7bgtbfxN-EJUtJDRYpO5V00L96Rldi3F3bt008X8sUdXK71hTta13NSkaCakAvQgaCP8yimMzmLyGgtBHcIgIbjg=]
*   **Impact:** Medium. While not directly about China, this supply chain check indicates extremely robust overall demand for NVIDIA's chips. This strong underlying demand could potentially cushion any negative surprises from the China market or make the China recovery less critical for NVIDIA to beat expectations.
*   **Consensus Check:** Overlooked/Non-consensus. While strong demand is generally acknowledged, a specific 10:1 demand-to-supply ratio from "Asia field checks" is a more granular and potentially non-consensus data point from a niche source.

**Contradictions and Gaps:**

*   **China Demand vs. Rejection:** The most significant contradiction is between the expectation of resumed H20 sales contributing to revenue and the report of China actively rejecting these compliant chips. This creates a high degree of uncertainty regarding the actual revenue impact from China in Q2 and beyond.
*   **Timing of China Revenue Recognition:** Even if H20 sales resume, there's a gap in consensus regarding when this revenue will materially hit NVIDIA's financials. Some analysts expect a Q2 boost, while others suggest it will be more impactful in H2 FY2026 or that NVIDIA's guidance might still exclude it due to uncertainty.
*   **Net Impact of 15% Revenue Share:** While the 15% revenue share is known, its precise impact on NVIDIA's gross margins and overall profitability from China sales, especially if volumes increase, is a detail to watch for in the earnings call.
*   **Effectiveness of China-Compliant Chips (B30A/RTX Pro):** Beyond H20, there are mentions of new China-compliant Blackwell derivatives (B30A/B20A and RTX Pro variants). The market's reception and sales volume of these new chips, and whether they can effectively counter domestic competition, remain a key unknown.